Ilya Pharma AB
  • Home
  • About
  • News
  • Science
  • Pipeline
  • Investors
  • Team
  • Stakeholders and partners
2023-03-03

Ilya Pharma have had a successful preIND meeting with the FDA related to the development of ILP100-Oral

The company have successfully conducted a preIND Type B meeting with the FDA regarding its developments of ILP100-Oral for the planned clinical development in cancer patients with colitis as a result of their cancer treatment. Today 30-40% of cancer patients receiving treatment with immune checkpoint inhibitors (ICIs) have to discontinue the treatment due to colitis. The Company is currently preparing the IND according to plan. 

  • To news list
  • Home
  • Twitter
  • Email
  • Phone
  • © Ilya Pharma AB 2025
Sitemap | Developed by: Perlin Systems AB